Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Catherine Drovetsky"'
Autor:
Kiranj Chaudagar, Hanna M. Hieromnimon, Rimpi Khurana, Brian Labadie, Taghreed Hirz, Shenglin Mei, Raisa Hasan, Jordan Shafran, Anne Kelley, Eva Apostolov, Ghamdan Al-Eryani, Kate Harvey, Srikrishnan Rameshbabu, Mayme Loyd, Kaela Bynoe, Catherine Drovetsky, Ani Solanki, Erica Markiewicz, Marta Zamora, Xiaobing Fan, Stephan Schürer, Alex Swarbrick, David B. Sykes, Akash Patnaik
Publikováno v:
Clinical Cancer Research. 29:1952-1968
Purpose: Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately 50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is associated with poor prognosis and responsiveness to standard-of-care therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5be68d3800b4a39cbb166c623f9acb33
https://doi.org/10.1158/1078-0432.ccr-22-3350
https://doi.org/10.1158/1078-0432.ccr-22-3350
Autor:
Akash Patnaik, David B. Sykes, Alex Swarbrick, Stephan Schürer, Xiaobing Fan, Marta Zamora, Erica Markiewicz, Ani Solanki, Catherine Drovetsky, Kaela Bynoe, Mayme Loyd, Srikrishnan Rameshbabu, Kate Harvey, Ghamdan Al-Eryani, Eva Apostolov, Anne Kelley, Jordan Shafran, Raisa Hasan, Shenglin Mei, Taghreed Hirz, Brian Labadie, Rimpi Khurana, Hanna M. Hieromnimon, Kiranj Chaudagar
Purpose:Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately 50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is associated with poor prognosis and responsiveness to standard-of-care therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cabfb09a9cb30f9f1e328f0b008a53c6
https://doi.org/10.1158/1078-0432.c.6563227.v1
https://doi.org/10.1158/1078-0432.c.6563227.v1
Autor:
Akash Patnaik, David B. Sykes, Alex Swarbrick, Stephan Schürer, Xiaobing Fan, Marta Zamora, Erica Markiewicz, Ani Solanki, Catherine Drovetsky, Kaela Bynoe, Mayme Loyd, Srikrishnan Rameshbabu, Kate Harvey, Ghamdan Al-Eryani, Eva Apostolov, Anne Kelley, Jordan Shafran, Raisa Hasan, Shenglin Mei, Taghreed Hirz, Brian Labadie, Rimpi Khurana, Hanna M. Hieromnimon, Kiranj Chaudagar
Supplementary Figure S1. The majority of Pb-Cre; PTENfl/fl Trp53fl/fl mice are de novo resistant to ADT. Supplementary Figure S2. ADT/PI3Ki combination therapy halts prostate tumor growth up to 14 days, followed by development of resistance in majori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::998c4977bf8201764c79ff7057327293
https://doi.org/10.1158/1078-0432.22551388
https://doi.org/10.1158/1078-0432.22551388
Autor:
Akash Patnaik, David B. Sykes, Alex Swarbrick, Stephan Schürer, Xiaobing Fan, Marta Zamora, Erica Markiewicz, Ani Solanki, Catherine Drovetsky, Kaela Bynoe, Mayme Loyd, Srikrishnan Rameshbabu, Kate Harvey, Ghamdan Al-Eryani, Eva Apostolov, Anne Kelley, Jordan Shafran, Raisa Hasan, Shenglin Mei, Taghreed Hirz, Brian Labadie, Rimpi Khurana, Hanna M. Hieromnimon, Kiranj Chaudagar
Supplementary Table S1. ADT + PI3Ki + PD-1 antibody leads to TAM activation within TME of PTEN/p53-deficient prostate tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d9c9f9283500d5546fd5f95fd33e150
https://doi.org/10.1158/1078-0432.22551385
https://doi.org/10.1158/1078-0432.22551385
Publikováno v:
Immunotherapy Weekly; 3/20/2023, p652-652, 1p